East China Medicine: DR10624 clinical research results released

East China Pharmaceutical announced that its controlling subsidiary Dor Biotech independently developed DR10624 will release clinical research results at the 2025 European Liver Disease Research Society annual meeting. DR10624 is a globally innovative long-acting triple agonist targeting fibroblast growth factor 21 receptor, glucagon receptor, and glucagon-like peptide-1 receptor, used to treat obesity combined with high triglycerides. The results of the Ib/IIa phase clinical study showed that after 12 weeks of treatment, the relative reductions in liver fat content in the various dose groups were 51.9%-75.8%, significantly higher than the placebo group's 26.3%. Additionally, DR10624 also demonstrated significant efficacy in lowering blood lipids and insulin resistance. Currently, DR10624 is conducting Phase II clinical studies in China and plans to obtain top-line results after unblinding in the third quarter of 2025.